Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04920383 · ClinicalTrials.gov registry record · Phase 1
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
A Phase 1 study, sponsored by Alpine Immune Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT04920383 is a Phase 1 study that was terminated before completion, run by Alpine Immune Sciences. The registered enrollment target is 29 participants.
The verdict
NCT04920383, a Phase 1 study, was terminated before completion, sponsored by Alpine Immune Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.
Interventions
- DRUG ALPN-202
- DRUG pembrolizumab KEYTRUDA®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04920383
The ClinicalTrials.gov registry entry for NCT04920383 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alpine Immune Sciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALPN-202 is the first listed.
NCT04920383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04920383 about?
NCT04920383 is a clinical study titled "ALPN-202 With PD-1 Inhibition in Advanced Malignancies". This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.
What is the current status of trial NCT04920383?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-06-22. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT04920383?
The interventions under investigation include: ALPN-202 (DRUG), pembrolizumab KEYTRUDA® (DRUG).
Who is sponsoring clinical trial NCT04920383?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.